4'-N-Octylacetophenone Synthesis Route for Fingolimod Intermediate

Securing a consistent source of pharmaceutical-grade intermediates is critical for R&D teams and procurement officers alike. Variability in impurity profiles or supply chain disruptions can delay clinical trials and impact commercial manufacturing timelines.

Detailed Chemical Synthesis Route and Reaction Mechanism

Efficient production of Fingolimod relies on a robust synthesis route for its precursors. The optimized manufacturing process begins with a Friedel-Crafts acylation, where octanoyl chloride reacts with benzene in the presence of aluminum chloride. This step typically yields n-octanophenone with over 99.0% purity by GC. Subsequent catalytic hydrogenation using 10% palladium on carbon converts this to n-octyl benzene with yields exceeding 90%.

The critical acylation step involves reacting n-octyl benzene with acetyl chloride and aluminum chloride to obtain 4'-n-Octylacetophenone, also known as 1-(4-Octylphenyl)ethanone. This key intermediate is achieved with yields above 95% by theory under controlled temperature conditions ranging from -10 to 35 °C. By avoiding laborious column chromatography and toxic solvents like pyridine, modern processes ensure higher industrial purity and environmental safety. This streamlined approach minimizes side products, ensuring the material meets strict pharmaceutical standards before moving to bromination and condensation steps.

Formulation Compatibility and Drop-in Replacement Advantages

For process chemists evaluating vendor switches, compatibility with existing workflows is paramount. Our material is designed to function as a seamless drop-in replacement for current sourcing strategies. Key advantages include:

• Consistent Impurity Profile: Batch-to-batch reproducibility ensures minimal adjustments to downstream purification steps.
• Solvent Flexibility: Compatible with standard solvents such as methylene dichloride, ethylene dichloride, or chloroform used in acylation.
• High Purity Standards: Delivered with comprehensive COA verification confirming purity levels suitable for API synthesis.
• Regulatory Support: Documentation aligns with global regulatory requirements for drug master files.

Factory-Direct Bulk Pricing Advantages and Supply Chain Stability

Procurement executives prioritize cost efficiency without compromising quality. As a dedicated global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. eliminates intermediary markups by offering factory-direct bulk price structures. We maintain a reliable supply of raw materials to prevent production bottlenecks, ensuring that tonnage requirements are met consistently throughout the year. Our logistics network supports timely delivery, reducing inventory holding costs for our partners. Quality assurance protocols are embedded at every stage, from raw material intake to final packaging, guaranteeing that every shipment meets the specified technical agreements.

Partnering with a trusted supplier mitigates risk and accelerates time-to-market for multiple sclerosis treatments. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.